A Novel 99mTc-Labeled Molecular Probe for Tumor Angiogenesis Imaging in Hepatoma Xenografts Model:A Preliminary Study

赵倩,李娟,殷雷,李玲,陈雪祺,马超,闫平,王荣福

DOI: https://doi.org/10.11735/j.issn.1671-170X.2013.12.B005

2013-01-01

Abstract:[Purpose] To evaluate 99mTc-radiolabeled RRL to be used for imaging of malignant tumors in vivo,and act as a new molecular probe targeting tumor angiogenesis.[Methods] The RRL peptide was designed and radiosynthesized with 99mTc by a one-step method.The radiolabeling efficiency and radiochemical purity were then characterized in vitro.99mTc-RRL was injected intravenously in HepG2xenograft-bearing BALB/c nude mice.Biodistribution and in vivo imaging were performed periodically.The relationship between tumor size and %ID uptake of 99mTc-RRL was also explored.[Results] The labeling efficiencies of 99mTc-RRL reached 76.9%±4.5%(n=6) within 30~60min at room temperature,and the radiochemical purity exceeded 96% after purification.In vitro stability experiment revealed the radiolabeled peptide was stable.Biodistribution data showed that 99mTc-RRL rapidly cleared from the blood and predominantly accumulated in the kidney and tumor.The specific uptake of 99mTc-RRL in tumor was significantly higher than that of unlabeled RRL blocking and free pertechnetate control test after injection(P<0.05).The ratio of the tumor-to-muscle exceeded 6.5,tumor-to-liver reached 1.98 and tumor-to-blood reached 1.95.In planar gamma imaging study,the tumors were imaged clearly at 2~6h after injection of 99mTc-RRL,whereas the tumor was not imaged clearly in blocking group.Immunohistochemical analysis verified the excessive vasculature of tumor.There was a linear relationship between the tumor size and uptake of 99mTc-RRL.[Conclusion] 99mTc-RRL can be used as a potential candidate for visualization of tumor angiogenesis in malignancies.